Affiliation
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, United KingdomIssue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
Essa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to Manage Atrial Fibrillation Secondary to Ibrutinib. JACC: CardioOncology. 2021 Mar;3(1):140–4.Journal
JACC CardioOncologyDOI
10.1016/j.jaccao.2020.11.016PubMed ID
34396314Additional Links
https://dx.doi.org/10.1016/j.jaccao.2020.11.016Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jaccao.2020.11.016
Scopus Count
Collections
Related articles
- Arrhythmia Patterns in Patients on Ibrutinib.
- Authors: Fazal M, Kapoor R, Cheng P, Rogers AJ, Narayan SM, Wang P, Witteles RM, Perino AC, Baykaner T, Rhee JW
- Issue date: 2021
- Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
- Authors: Aw A, Brown JR
- Issue date: 2017 Jul
- Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
- Authors: O'Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S, Stiehler L, Martin L, Coldewey SM, Collino M, Thiemermann C
- Issue date: 2019
- Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
- Authors: Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A
- Issue date: 2018 Jun 11
- Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
- Authors: Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R
- Issue date: 2019 Aug